Antibodies elicited by the widely deployed rVSV-EBOV Ebola virus vaccine mirror those of disease survivors, animal models and other vaccine platforms. Notably, neutralizing antibodies are consistently elicited from a recurring pair of germline genes.
This is a preview of subscription content, log in via an institution to check access.
References
Ehrhardt, S. A. Nat. Med. s41591-019-0602-4 (2019).
Corti, D. et al. Science 351, 1339–1342 (2016).
Misasi, J. et al. Science 351, 1343–1346 (2016).
Davis, C. W. et al. Cell 177, 1566–1582 (2019).
Saphire, E. O. et al. Cell 174, 938–952 (2018).
Bornholdt, Z. A. et al. Science 351, 1078–1083 (2016).
Rijal, P. et al. Cell Rep. 27, 172–186.e7 (2019).
Henao-Restrepo, A. M. et al. Lancet 389, 505–518 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Saphire, E.O. A glimpse into immune responses evolving against Ebola virus. Nat Med 25, 1470–1471 (2019). https://doi.org/10.1038/s41591-019-0607-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-019-0607-z
- Springer Nature America, Inc.